Year Founded
2019
Ownership
Private
Employees
~29
Stage
Commercial
Modalities
Fermentation-based biomanufacturing

Cellibre General Information

Cellibre is developing biosynthesis and chemical synthesis approaches for manufacturing cannabinoids and other natural products. The company has commercial sales of rare cannabinoids including CBC, CBT, CBDV and THCV to the health and wellness sector.

Contact Information

Website
Primary Industry
[ "Biotech", "CDMO" ]
Corporate Office

Drug Pipeline

CBC
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Cellibre's pipeline data

Book a demo

Key Partnerships

Ajinomoto Health & Nutrition North America

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Cellibre Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Cellibre's complete valuation and funding history, request access »